Sort
48,018 grants matching “immunotherapy”
SINGLE-CELL MULTI-OMICS INTEGRATION TO EXPLOIT AUTOIMMUNITY INDUCED BY CHECKPOINT IMMUNOTHERAPY IN MALIGNANT PLEURAL MESOTHELIOMA
$2,000,000Baylor College Of Medicine · · FY2022 · Department of the Army
COMBINING IMMUNOTHERAPY AND MYC SYNTHETIC LETHALITY FOR METASTATIC BREAST CANCER
$2,000,000Helsingin Yliopisto · · FY2021 · Defense Health Agency
QuSeC-TAQS: Nanodiamond Quantum Sensing for Four-Dimensional Live-Cell Imaging
$2,000,000Shengwang Du · University Of Texas At Dallas · · FY2023 · MPS
Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma
$2,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2023 · CA
NRT-QISE-AI: Middle Tennessee Interdisciplinary Graduate Research and Training in Quantum Information Science and AI
$2,000,000Wandi Ding · Middle Tennessee State University · · FY2025 · EDU
Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma
$2,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2022 · CA
TOPIC 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER- MOONSHOT
$2,000,000Guixin Shi · Diagnologix, Llc · N44 · FY2019 · CA
Genetic Approaches to Cancer Immunotherapy
$1,999,999Michel Sadelain · Sloan-Kettering Inst Can Research · P01 · FY2006 · CA
Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer
$1,999,998Beatrice Langton-Webster · Cancer Targeted Technology, Llc · R44 · FY2025 · CA
The UCLA Center for In Vivo Imaging in Cancer Biology
$1,999,943University Of California Los Angeles · P50 · FY2005 · CA
Antibody Targeted Radiation and Immunotherapy for the Treatment of Solid Tumors
$1,999,788Andrew A. Raubitschek · Beckman Research Institute/City Of Hope · P01 · FY2010 · CA
TOPIC 397 - MICROFLUIDIC VORTEX SHEDDING: A LOW-COST, HIGH EFFICIENCY METHOD FOR GENETIC MODIFICATION TO SUPPORT CELL ENGINEERING FOR CELL-BASED IMMUNOTHERAPIES
$1,999,646Ryan Pawell · Indee, Inc · N44 · FY2022 · CA
Genetic, Cellular and Molecular Mechanisms in Autoimmunity to Retina
$1,999,468Rachel R. Caspi · National Eye Institute · ZIA · FY2011 · EY
MOONSHOT - TOPIC 372 - DEVELOPMENT AND VALIDATION OF NON-MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS.
$1,999,381Adriann Sax · Vetigenics Llc · N44 · FY2021 · CA
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
$1,999,002Roger L Shapiro · Harvard School Of Public Health · U01 · FY2021 · AI
Genetic Approaches to Cancer Immunotherapy
$1,998,048Michel Sadelain · Sloan-Kettering Inst Can Research · P01 · FY2008 · CA
Nanosystems Biology Cancer Center
$1,997,668James R. Heath · Institute For Systems Biology · U54 · FY2019 · CA
LICI Microbiome and Genetics Core
$1,996,346Colm Ohuigin · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Vulnerabilities in osteosarcoma and breast cancer
$1,995,196Jing Huang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES
$1,995,174Jelena Levi · Cellsight Technologies, Inc. · N44 · FY2022 · CA
Branch Clinical Research Core
$1,994,665Ronald Gress · Division Of Basic Sciences - Nci · ZID · FY2010 · CA
Specialized Program of Research Excellence
$1,993,608Jennifer R Grandis · University Of Pittsburgh At Pittsburgh · P50 · FY2012 · CA
SPORE in Prostate Cancer
$1,993,426Samuel R Denmeade · Johns Hopkins University · P50 · FY2017 · CA
The Delta Ecology of NSCLC Treatment
$1,992,935Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2024 · CA
ADULT AIDS CLINICAL TRIALS UNIT (AACTU)
$1,992,814University Of Rochester · U01 · FY2004 · AI